High-Quality Orforglipron CAS 2212020-52-3 - Top China Suppliers & Factory for High-Quality Pharmaceutical Ingredients Manufacturers, Service
Product Description
Orforglipron is an investigational oral medication being developed by Eli Lilly for treating type 2 diabetes and obesity. It is a non-peptide GLP-1 receptor agonist, meaning it mimics the effects of a natural hormone that regulates blood sugar and appetite. Clinical trials have shown that orforglipron can lead to significant weight loss and improved blood sugar control in people with type 2 diabetes and obesity.
Mechanism & Efficacy
Orforglipron is a novel GPR40 (FFAR1) agonist, designed to enhance insulin secretion in response to elevated glucose levels. By selectively activating GPR40 receptors in pancreatic β-cells, Orforglipron improves glucose-dependent insulin release, potentially offering benefits in type 2 diabetes management. Early clinical data suggest improvements in glycemic control, HbA1c reduction, and beta-cell function, making it a promising candidate for research and development.
Dosage & Clinical Use
In original research studies, Orforglipron has been administered as an oral tablet, with doses typically ranging from 10 mg to 50 mg per day, adjusted according to clinical trial protocols and patient response. Dosage may vary in experimental studies, and all applications should follow ethical and regulatory guidelines.
What is Orforglipron?
Orforglipron is an investigational oral medication developed by Eli Lilly, primarily targeted for the treatment of type 2 diabetes and obesity.
How does Orforglipron work in the body?
It functions as a non-peptide GLP-1 receptor agonist and a novel GPR40 (FFAR1) agonist. It mimics natural hormones to regulate appetite and enhances glucose-dependent insulin secretion from pancreatic β-cells.
What are the main benefits observed in clinical trials?
Clinical trials have demonstrated that it can lead to significant weight loss, improved blood sugar control, reduction in HbA1c levels, and enhanced beta-cell function.
How is this medication administered?
In original research studies, Orforglipron is administered orally in the form of a daily tablet.
What is the typical dosage used in research studies?
Doses in clinical trials typically range from 10 mg to 50 mg per day. The exact dosage is adjusted based on specific trial protocols and individual patient response.
